	US 12,226,465 B2
	Humanized monoclonal advanced glycation end-product antibody
Lewis S. Gruber, Chicago, IL (US)
Assigned to Siwa Corporation, Chicago, IL (US)
Filed by Siwa Corporation, Chicago, IL (US)
Filed on Oct. 28, 2022, as Appl. No. 18/050,915.
Prior Publication US 2023/0295282 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); C07K 16/18 (2006.01); C07K 16/44 (2006.01); G03G 21/16 (2006.01)

CPC A61K 39/00 (2013.01) [A61K 47/6843 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); C07K 16/18 (2013.01); C07K 16/44 (2013.01); G03G 21/1685 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. A method of treating cancer in a human subject, comprising:

administering to the subject a composition comprising a humanized monoclonal advanced glycation end-product antibody, and

a pharmaceutically acceptable carrier,

wherein the antibody binds a carboxymethyllysine-modified protein or peptide.